SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 138 filers reported holding SAGE THERAPEUTICS INC in Q4 2015. The put-call ratio across all filers is 1.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $14,184,711 | +12.0% | 301,674 | -0.0% | 0.01% | +16.7% |
Q1 2023 | $12,660,297 | +10.0% | 301,723 | -0.1% | 0.01% | 0.0% |
Q4 2022 | $11,513,474 | -2.7% | 301,874 | -0.1% | 0.01% | 0.0% |
Q3 2022 | $11,828,000 | +21.3% | 302,033 | +0.1% | 0.01% | +20.0% |
Q2 2022 | $9,748,000 | -2.4% | 301,809 | +0.0% | 0.01% | +25.0% |
Q1 2022 | $9,987,000 | -19.5% | 301,728 | +3.5% | 0.00% | 0.0% |
Q4 2021 | $12,404,000 | -3.7% | 291,580 | +0.3% | 0.00% | -20.0% |
Q3 2021 | $12,878,000 | -16.8% | 290,645 | +6.7% | 0.01% | -16.7% |
Q2 2021 | $15,471,000 | -17.8% | 272,334 | +8.3% | 0.01% | -25.0% |
Q1 2021 | $18,816,000 | -13.4% | 251,385 | +0.1% | 0.01% | -11.1% |
Q4 2020 | $21,727,000 | +41.6% | 251,141 | +0.0% | 0.01% | +28.6% |
Q3 2020 | $15,346,000 | +35.8% | 251,082 | +5.2% | 0.01% | +16.7% |
Q2 2020 | $11,302,000 | +64.9% | 238,679 | 0.0% | 0.01% | +20.0% |
Q1 2020 | $6,855,000 | -89.1% | 238,679 | -72.7% | 0.01% | -84.8% |
Q4 2019 | $63,099,000 | -57.0% | 874,109 | -16.4% | 0.03% | -58.8% |
Q3 2019 | $146,751,000 | -23.5% | 1,045,957 | -0.1% | 0.08% | -21.6% |
Q2 2019 | $191,718,000 | +14.9% | 1,047,212 | -0.2% | 0.10% | +14.6% |
Q1 2019 | $166,880,000 | +67.1% | 1,049,164 | +0.6% | 0.09% | +48.3% |
Q4 2018 | $99,863,000 | -25.6% | 1,042,955 | +9.7% | 0.06% | -10.4% |
Q3 2018 | $134,277,000 | +50.1% | 950,773 | +66.3% | 0.07% | +45.7% |
Q2 2018 | $89,470,000 | +12.8% | 571,652 | +16.1% | 0.05% | +15.0% |
Q1 2018 | $79,313,000 | -8.2% | 492,411 | -6.1% | 0.04% | -2.4% |
Q4 2017 | $86,405,000 | +192.4% | 524,590 | +10.6% | 0.04% | +192.9% |
Q3 2017 | $29,551,000 | -27.1% | 474,336 | -6.8% | 0.01% | -30.0% |
Q2 2017 | $40,525,000 | -9.0% | 508,856 | -18.8% | 0.02% | -13.0% |
Q1 2017 | $44,537,000 | -22.2% | 626,666 | -44.1% | 0.02% | -23.3% |
Q4 2016 | $57,259,000 | +2.8% | 1,121,403 | -7.3% | 0.03% | +3.4% |
Q3 2016 | $55,724,000 | +30.4% | 1,210,082 | -14.7% | 0.03% | +26.1% |
Q2 2016 | $42,724,000 | +3.5% | 1,417,977 | +10.1% | 0.02% | +4.5% |
Q1 2016 | $41,287,000 | -40.7% | 1,287,805 | +7.8% | 0.02% | -37.1% |
Q4 2015 | $69,630,000 | +59.4% | 1,194,331 | +15.7% | 0.04% | +59.1% |
Q3 2015 | $43,687,000 | -12.7% | 1,032,310 | +50.6% | 0.02% | -4.3% |
Q2 2015 | $50,035,000 | +69.6% | 685,410 | +16.7% | 0.02% | +76.9% |
Q1 2015 | $29,510,000 | +303.1% | 587,500 | +193.8% | 0.01% | +333.3% |
Q4 2014 | $7,320,000 | +16.2% | 200,000 | 0.0% | 0.00% | 0.0% |
Q3 2014 | $6,300,000 | – | 200,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sio Capital Management, LLC | 179,200 | $29,516,000 | 16.65% |
TRV GP II, LLC | 547,916 | $90,247,000 | 16.25% |
Opus Point Partners Management, LLC | 71,000 | $11,694,000 | 10.12% |
Casdin Capital, LLC | 250,000 | $41,178,000 | 10.03% |
RA Capital Management | 455,173 | $74,972,000 | 6.27% |
Crawford Lake Capital Management, LLC | 154,278 | $25,411,000 | 6.00% |
Palo Alto Investors LP | 810,806 | $133,548,000 | 5.75% |
GREAT POINT PARTNERS LLC | 200,000 | $32,942,000 | 5.62% |
BB BIOTECH AG | 1,042,439 | $171,700,000 | 4.84% |
Crawford Lake Capital Management, LLC | 92,300 | $15,203,000 | 3.59% |